Drug details

Truxima (rituximab-abbs injection)

type of DMARDs, Other, Antineoplastics, Anti-CD20 Monoclonal Antibodies

Truxima (rituximab-abbs) is a CD20-directed cytolytic antibody indicated for the treatment of adult patients with non-Hodgkin's lymphoma (NHL): relapsed or refractory, low grade or follicular, CD20-positive B- cell NHL as a single agent; previously untreated follicular, CD20-positive, B-cell NHL in combination with first line chemotherapy and, in patients achieving a complete or partial response to a rituximab product in combination with chemotherapy, as single-agent maintenance therapy; and non-progressing (including stable disease), low-grade, CD20-positive, B- cell NHL as a single agent after first-line cyclophosphamide, vincristine, and prednisone (CVP) chemotherapy.

This drug may have the following side effects:

• fever,
• chills,
• weakness
• low lymphocytes in the blood (lymphopenia),
• infection, and

The following drugs are related to Truxima, either as a replacement or used together:

• Adcetris (brentuximab vedotin)
• YESCARTA (axicabtagene ciloleucel suspension for intravenous infusion)
• Beleodaq (belinostat for injection for intravenous use)
• Vivimusta (bendamustine hydrochloride injection)
• Breyanzi (lisocabtagene maraleucel suspension for intravenous infusion)
• Ontak (denileukin diftitox)
• Epkinly (epcoritamab-bysp injection)
• Gazyva (obinutuzumab injection)
• Imbruvica (ibrutinib capsules)
• Keytruda (pembrolizumab for injection)
• Kymriah (tisagenlecleucel suspension for intravenous infusion)
• Zynlonta (loncastuximab tesirine-lpyl for injection)
• Monjuvi (tafasitamab-cxix injection)
• Vanflyta (quizartinib tablets)
• Rituxan (rituximab)
• Rituxan Hycela (rituximab and hyaluronidase human injection)
• Tazverik (tazemetostat tablets)